e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Anti-infective treatment and resistance in respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia
S. Hanada, S. Suzuki, H. Uruga, H. Takaya, A. Miyamoto, N. Morokawa, A. Kurosaki, K. Kishi (Minato-ku, Japan)
Source:
Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Session:
Anti-infective treatment and resistance in respiratory infections
Session type:
Poster Discussion
Number:
4378
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Hanada, S. Suzuki, H. Uruga, H. Takaya, A. Miyamoto, N. Morokawa, A. Kurosaki, K. Kishi (Minato-ku, Japan). Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia. Eur Respir J 2012; 40: Suppl. 56, 4378
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Systemic corticosteroid for treating severe community-acquired pneumonia
Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation
Year: 2015
Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients
Source: Eur Respir J 2015; 45: 463-472
Year: 2015
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Efficacy of corticosteroids in hospital treated community-acquired pneumonia
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
Hospital-acquired pneumonia in patients receiving immunosuppressive therapy
Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections
Year: 2009
Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Ertapenem therapy for community-acquired pneumonia in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005
Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia
Source: Eur Respir J 2011; 37: 36-41
Year: 2011
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
Intravenous steroids in the treatment of community-acquired pneumonia (CAP)
Source: Eur Respir J 2004; 24: Suppl. 48, 50s
Year: 2004
Efficacy and safety of stepwise therapy in patients with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 377s
Year: 2006
Oral antibiotics prior to hospitalisation for community-acquired pneumonia
Source: Eur Respir J 2008; 31: 478-479
Year: 2008
Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial
Source: Eur Respir J, 58 (2) 2002535; 10.1183/13993003.02535-2020
Year: 2021
Efficacy of α-tocoferol in the treatment of patients with pneumonia
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
Outpatient treatment of community-acquired pneumonia in the elderly
Source: Eur Respir J 2002; 20: Suppl. 38, 355s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept